Toll Free: 1-888-928-9744

C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Pipeline Review, H1 2016

Published: May 31, 2016 | Pages: 37 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Pipeline Review, H1 2016', provides in depth analysis on C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) targeted pipeline therapeutics. 

The report provides comprehensive information on the C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3)
- The report reviews C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) targeted therapeutics and enlists all their major and minor projects 
- The report assesses C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) Overview 6 Therapeutics Development 7 C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Products under Development by Stage of Development 7 C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Products under Development by Therapy Area 8 C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Products under Development by Indication 9 C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Products under Development by Companies 12 C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 18 C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Companies Involved in Therapeutics Development 20 Axikin Pharmaceuticals, Inc. 20 Mitsubishi Tanabe Pharma Corporation 21 Pharmaxis Limited 22 Toray Industries, Inc. 23 C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Drug Profiles 24 ASM-8 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 AXP-1275 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 MT-0814 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 PXS-2200 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecule to Antagonize CCR3 for Undisclosed Indication - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Dormant Projects 30 C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Discontinued Products 31 C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3) - Featured News & Press Releases 32 Apr 17, 2012: Pharmaxis Completes Phase II Clinical Study With ASM8 In Asthma Patients 32 Sep 29, 2011: Pharmaxis Completes Enrollment In Phase II Asthma Study 32 Dec 07, 2010: Pharmaxis Initiates Phase II Trial Of ASM8 In Asthma Patients 33 Mar 11, 2010: Pharmaxis Completes Phase II Clinical Study With ASM8 In Asthma Patients 33 Jan 12, 2009: TOPIGEN Pharmaceuticals Reports Phase 2 Results of TPI ASM8 in Asthma Patients 34 Appendix 36 Methodology 36 Coverage 36 Secondary Research 36 Primary Research 36 Expert Panel Validation 36 Contact Us 36 Disclaimer 37
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 15 Number of Products by Stage and Route of Administration, H1 2016 17 Number of Products by Stage and Molecule Type, H1 2016 19 Pipeline by Axikin Pharmaceuticals, Inc., H1 2016 20 Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 21 Pipeline by Pharmaxis Limited, H1 2016 22 Pipeline by Toray Industries, Inc., H1 2016 23 Dormant Projects, H1 2016 30 Discontinued Products, H1 2016 31


List of Figures
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Top 10 Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Actions, H1 2016 15 Number of Products by Routes of Administration, H1 2016 16 Number of Products by Stage and Routes of Administration, H1 2016 16 Number of Products by Molecule Types, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 18

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to dri

Read More...

Global glycerol market size is likely to exceed USD 3 billion by 2022, as per a new research report by Radiant Insights, Inc. Regulatory push for promoting bio-diesel production is expected to boost glycerol demand over the forecast period, with expe

Read More...

Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expected

Read More...

Global outsourced customer care services market is projected to reach USD 84.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Swelling need for interaction through non-voice channels is estimated to boost global demand over t

Read More...

Global compressed air treatment equipment market is projected to reach USD 8.59 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing implementation of this equipment in various industry sectors such as healthcare & pharmace

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify